Remove Biosimilars Remove Presentation Remove Process Improvement
article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

These developments present important opportunities to improve affordability and access— provided that the program is designed and implemented in a way that centers patient needs. Even well-intentioned policies can create access disparities if communication and operational support are lacking.

article thumbnail

The next frontier: Global leadership in biopharma

Express Pharma

Sasmitha Sahu, Managing Consultant, GlobalData states, “While India has demonstrated success in generic drug production, the same is not true for novel and biosimilar biopharma products.” This positions India as a viable and resilient alternative to China.